Our Story
Onyx BioPartners was founded by Sintija Ursulska, a pharmaceutical scientist with corporate pharmaceutical experience across clinical development, regulatory strategy, medical affairs, and commercialization within the life sciences industry.
We have supported cross-functional life science teams, contributed to evidence generation strategies, and navigated complex regulatory and commercial landscapes across international markets.
Our passion lies in bridging the gap between scientific innovation and real-world impact — ensuring promising therapies, medical technologies, and science-backed supplements do not stall in development, but reach patients and consumers with strategic clarity and commercial strength.
Onyx BioPartners was established to provide growing biotech, medtech, and pharmaceutical companies with the structured guidance often only available inside large corporations — combining scientific rigor, regulatory intelligence, and financial strategy to build approvable, fundable, and scalable health innovation.
Our Team
Behind Onyx BioPartners is a multidisciplinary network of senior experts across the life sciences value chain, engaged based on the strategic needs of each project.
With 20+ years combined experience in pharmaceuticals, we support our clients with structured, scientific and evidence-based approach.
R&D Strategy
Scientific and development specialists with experience in preclinical planning, translational research, and structured study design for both pharmaceutical and science-backed supplement innovation.
Regulatory Strategy
Regulatory experts with hands-on experience across EU and MENA markets, ensuring region-specific compliance, dossier excellence, and strategic submission positioning.
Commercial Strategy
Global market access and commercialization specialists with experience in pricing strategy, reimbursement positioning, and international product launches.
Financial Services
Financial and operational advisors with specific expertise in pharmaceutical business models, capital structuring, funding readiness, and scalable growth planning.